The company develops residential villas and apartments in Ahmedabad, Gujarat, and has recently expanded its charter to include agricultural product trading and financial investments.
The company lacks a sustainable moat, as evidenced by the total cessation of core real estate operations in FY2025 and a shift toward generic commodity trading and security investments. High ROE and ROCE figures are distorted by a very small capital base and non-operating income rather than durable pricing power or cost advantages.
Management has diverted significant portions of IPO proceeds into interest-free loans and advances to related parties and promoters. The track record shows a shift away from productive asset creation toward circular financing and non-core investments with no clear return profile.
The company's transition from real estate to generic commodity trading and security investments proved to be a shell game for capital extraction. The interest-free loans to related parties were never recovered, and the inventory, which auditors could not physically verify, was eventually written off as non-existent or worthless. As the core business generated zero revenue, the company became a hollow entity, with the remaining cash drained through circular financing and unconfirmed supplier advances, leaving shareholders with a worthless claim on a non-operating business.
RichFakir rates SVS Ventures Ltd's business quality as mediocre — 46/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, SVS Ventures Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on SVS Ventures Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of SVS Ventures Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →